Kraig Biocraft Laboratories, INC

Kraig Biocraft Laboratories has entered into a $10 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. to support the expansion and commercialization of its spider silk production.

Kraig Biocraft Laboratories issued one share of Series A preferred stock to its CEO, Kim Thompson, in exchange for $20,000 of debt cancellation.

Kraig Biocraft Laboratories, Inc. reported a net loss of $2.84 million for the nine months ended September 30, 2025, while increasing cash reserves through a standby equity purchase agreement.

Kraig Biocraft Laboratories, Inc. reported a significantly reduced net loss for the second quarter of 2025, driven by lower operating expenses and a capital raise, despite ongoing going concern doubts.

Kraig Biocraft Laboratories reports ongoing losses in Q1 2025, emphasizing the need for additional capital to sustain operations and execute its business plan.

Kraig Biocraft Laboratories reported no revenue for the third quarter of 2024, with a net loss of $433,200, while continuing to focus on research and development and scaling production of its spider silk technology.

Kraig Biocraft Laboratories reported a net loss of $2.11 million for the six months ended June 30, 2024, as operating expenses significantly increased.

Kraig Biocraft Laboratories reported a net loss of $507,875 for the first quarter of 2024, as the company continues to focus on research and development and production improvements.

Kraig Biocraft Laboratories reports its financial results for the year ended December 31, 2024, highlighting ongoing efforts in recombinant spider silk production and strategic collaborations.

Kraig Biocraft Laboratories' 10-K filing details advancements in recombinant spider silk production, strategic partnerships, and ongoing financial hurdles.

Kraig Biocraft Laboratories, Inc.'s Chief Operating Officer, Jonathan Rice, has increased his direct beneficial ownership by exercising warrants to acquire 314,636 shares of Class A Common Stock.

Kimberly Kraig Thompson, CEO of Kraig Biocraft Laboratories, Inc., acquired 27,500 shares of common stock at a price of $0.0906 per share on March 31, 2025.

Kimberly Kraig Thompson, CEO of Kraig Biocraft Laboratories, reports the acquisition of 62,500 shares of common stock at a price of $0.0906 per share on March 31, 2025.

Chief Operating Officer of Kraig Biocraft Laboratories, Jonathan Richard Rice, recently exercised stock options, increasing his holdings in Class A Common Stock.

Kraig Biocraft Laboratories files a pre-effective amendment to its Form S-1 registration statement, primarily related to exhibits and legal opinions, with no new securities being registered.

Kraig Biocraft Laboratories files an amendment to its Form S-1 registration statement related to a proposed offering of Class A Common Stock.

Kraig Biocraft Laboratories has filed a registration statement for the potential resale of up to 207,787,193 shares of its common stock by YA II PN, Ltd., under a standby equity purchase agreement.

Kraig Biocraft Laboratories files an amendment to its registration statement to include updated financial information and details about a proposed public offering.